RET TKI: Potential role in thyroid cancers

  • Antonelli A
  • Fallahi P
  • Ferrari S
 et al. 
  • 12


    Mendeley users who have this article in their library.
  • 37


    Citations of this article.


The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (RET/PTC) or signaling kinases (vascular endothelial growth factor receptor [VEGFR]) involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies able to inhibit RET(sorafenib, imatinib, vandetanib) in stabilizing the course of the disease. The aim of the introduction of these targeted therapies is to extend life duration assuring a good quality of life; however, further studies are needed to reach these goals.

Author-supplied keywords

  • Medullary thyroidcancer
  • Papillary thyroid cancer
  • Targeted molecular therapies
  • Tyrosine kinase inhibitors

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Alessandro Antonelli

  • Poupak Fallahi

  • Silvia Martina Ferrari

  • Caterina Mancusi

  • Michele Colaci

  • Libero Santarpia

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free